demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 all comersCOVID-19 severe or critically
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 severe or critically
sarilumab CORIMUNO-SARI-1 ... sarilumab Sanofi phase 3 US sarilumab Sanofi phase 3 outside US REMAP-CAP sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose Lescure ...
sarilumab low dose (200mg) sarimulab phase 2 low dose Lescure ...

1 studies excluded by filtering options 1

5633 ARI-RAF (Della-Torre), 2020 1130not a RCTrisk of bias not avaialble